Page 2508 - Williams Hematology ( PDFDrive )

2479
2478 Index Index 2479

in thrombolysis, 1855t microscopic appearance, 1834, 1835f thrombolysis and, 1855
in vessel integrity and development, open canalicular system, 1835f, 1836 for transfusion. See Platelet transfusion
1857 organelles, 1840 von Willebrand factor binding to, 2168
gene expression plasma membrane, 1834, 1835f, 1836, Platelet satellitism, 22, 22f
gene variants associated with disease, 1837f Platelet transfusion
1850 in newborn, 107–108 adverse effects, 2381, 2385
gene variants associated with platelet in older persons, 134–135 for aplastic anemia, 522
traits, 1850–1851, 1850f reference ranges, 18t for bleeding, 2385
genomics, 1850 release, 72 bleeding time and, 2384, 2384f
proteomics, 1853–1854 response, 247 for disseminated intravascular coagulation,
transcriptomics, 1851–1853, 1852f ristocetin binding to, 2168, 2173 2213
granule formation, 1818, 1819f satellitism, 1995, 1995f dose and response to, 2383–2384
granule-plasma membrane fusion, 1849 secretory machinery and secretion for heparin-induced thrombocytopenia,
inflammatory response in monocytes and, adhesive glycoproteins, 1846–1847t 2032
1970f α granules, 1843–1845, 1844f, 1848 human leukocyte antigens typing and,
interactions with endothelial cells, dense bodies, 1835f, 1843 2356
1978–1979 exocytosis, 1849–1850 incidence, 2381
interactions with leukocytes, 1830–1831f, exosomes, 1848 indications, 2383
1852f, 1857f, 1978–1979 lysosomes, 1843 for inherited platelet disorders, 2061
interaction with monocytes and secretion, 1849 for invasive procedures, 2384
macrophages, 1059 shape change, spreading, contraction, and for myelodysplastic syndromes, 1357
life span, 1993, 2381–2382, 2382f clot retraction for neonatal alloimmune
membrane glycoproteins, 1858 contraction and clot retraction, 1842– thrombocytopenia, 2013
C1q receptors, 1873 1843 for paroxysmal nocturnal hemoglobinuria
CD40 ligand, 1872–1873 overview, 1832–1833t, 1840 during pregnancy, 580
cell-surface adhesion receptors and shape change, 1835f, 1840–1841 platelet increments, corrected count
membrane proteins, 1868–1870 spreading and surface-induced increments, and transfusion
Fas ligand, LIGHT, TRAIL, 1873 activation, 1841–1842 interval, 2387–2388
glycosylphosphatidylinositol-anchored signaling pathways, 1874–1886, 1875f preparation methods
proteins, 1871 agonist-induced platelet activation, apheresis, 2386
GMP-33, 1873 1874–1881 concentrates from whole blood, 2386,
integrins, 1861–1865 adenosine diphosphate, 1874–1876 2386f
lectin-containing receptors, 1870–1871 angiotensin II, 1879 for extended storage, 2388–2389, 2389t
leucine-rich repeat glycoprotein chemokines, 1878 irradiation, 2388
receptors, 1865–1868, 1866f, 1867f collagen, 1879–1881, 1880f pathogen reduction, 2388
leukosialin, sialophorin, 1873 epinephrine, 1876 response and, 2386–2387, 2387f
lysosome-associated membrane GpIb/IX/V, 1881 volume reduction, 2388
proteins, 1873 G-protein–coupled receptors, 1874, prophylactic vs. therapeutic, 2383
matrix metalloproteinases, 1874 1875f refractoriness to, 2385
peroxisome proliferator-activated lipid mediators, 1878 response to, 2000, 2381–2382, 2382f, 2387f
receptors, 1873–1874 serotonin, 1878–1879 for thrombocytopenic patient on
scavenger receptors, 1872 tachykinins, 1878 anticoagulant therapy, 2385
tetraspanins, 1871 thrombin, 1877, 1877f for thrombotic thrombocytopenic
tyrosine kinase receptors, 1871–1872 thrombospondin, 1879 purpura, 2256
membranes, 1818 thromboxane A , 1876–1877 Platelet-type (pseudo-) von Willebrand
2
morphology and biochemistry, 21–22, vasopressin, 1879 disease, 2050–2051, 2165t, 2174
1834–1839 inhibitory Platelet volume distribution width (PDW), 17
cytoskeletal elements, 1836–1839 CD39, 1885–1886 Platinating drugs, resistance to, 319t
actin filaments, 1838–1839, 1839f nitric oxide, 1885 Platinum analogues, 329
membrane skeleton, 1835f, prostaglandins, 1885 PLC (phospholipase C), 1016, 1874,
1837–1838, 1838f intermediate signaling molecules 2057–2058
microtubules, 1835f, 1838 calcium, 1837f, 1881–1882 PLC-β (phospholipase C-β ) deficiency,
2
2
proteins, 1832–1833t, 1858–1859t calcium-dependent proteases, 1883 2057–2058
dense tubular system/sarcoplasmic integrin α β , 1883–1885 PLC-γ (phospholipase Cγ ), 1178, 1529
1
1
IIb 3
reticulum, 1835f, 1836 phosphoinositide 3′-kinases, 1882 PLC-γ (phospholipase Cγ ), 1538
2
lipid rafts, 1836 small G proteins, 1882–1883 Pleckstrin, 1841 2

Kaushansky_index_p2393-2506.indd 2479 9/21/15 3:22 PM